Should catheter ablation be the preferred therapy for reducing icd shocks?: Ventricular tachycardia ablation versus drugs for preventing icd shocks: Role of adjuvant antiarrhythmic drug therapy

Circulation: Arrhythmia and Electrophysiology

Volumn 2, Issue 6, 2009, Pages 705-711

  Kowey, Peter R ^a,b,c   Patel, Chinmay ^a,c   Yan, Gan Xin ^a,b,c   Kocovic, Dusan ^d  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d NONE

Author keywords

Adjuvant therapy; Antiarrhythmic drug therapy; ICD shocks; Implantable cardioverter defibrillator; Ventricular arrhythmia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; DRONEDARONE; METOPROLOL; SOTALOL;

BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CATHETER ABLATION; CLINICAL TRIAL; DEFIBRILLATION; DEFIBRILLATOR; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERMETHOD COMPARISON; LUNG TOXICITY; NEUTROPENIA; NOTE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHOCK; THYROID DISEASE; TORSADE DES POINTES; TREATMENT INDICATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ARTICLE; CARDIOVERSION; EQUIPMENT; EVIDENCE BASED MEDICINE; HEART VENTRICLE FIBRILLATION; INSTRUMENTATION; RECURRENT DISEASE; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; EQUIPMENT FAILURE; EVIDENCE-BASED MEDICINE; HUMANS; QUALITY OF LIFE; RECURRENCE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 73949100824     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.109.893628     Document Type: Note

References (56)

1. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE, Weisfeldt ML. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303: 322-324.
2. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350-e408.
3. DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med. 2003; 349:1836-1847.
4. Reiffel JA. Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. J Cardiovasc Pharmacol Ther. 2005; 10(Suppl 1):S45-S58.
5. Al-Khatib SM, LaPointe NM, Curtis LH, Kramer JM, Swann J, Honig P, Califf RM. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol. 2003;91:91-94.
6. Hine LK, Gross TP, Kennedy DL. Outpatient antiarrhythmic drug use from 1970 through 1986. Arch Intern Med. 1989;149:1524-1527.
7. Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med. 2008;23(Suppl 1):13-19.
8. Dorian P, Philippon F, Thibault B, Kimber S, Sterns L, Greene M, Newman D, Gelaznikas R, Barr A. Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 2004;1:540-547.
9. Nanthakumar K, Paquette M, Newman D, Deno DC, Malden L, Gunderson B, Gilkerson J, Greene M, Heng D, Dorian P. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. Am Heart J. 2000;139:797-803.
10. Rosenqvist M, Beyer T, Block M, den DK, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study: European 7219 Jewel ICD Investigators. Circulation. 1998;98:663-670.
11. Pelletier D, Gallagher R, Mitten-Lewis S, McKinley S, Squire J. Australian implantable cardiac defibrillator recipients: quality-of-life issues. Int J Nurs Pract. 2002;8:68-74.
12. Ahmad M, Bloomstein L, Roelke M, Bernstein AD, Parsonnet V. Patients' attitudes toward implanted defibrillator shocks. Pacing Clin Electrophysiol. 2000;23:934-938.
13. Heller SS, Ormont MA, Lidagoster L, Sciacca RR, Steinberg S. Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol. 1998;21:1207-1215.
14. Sola CL, Bostwick JM. Implantable cardioverter-defibrillators, induced anxiety, and quality of life. Mayo Clin Proc. 2005;80:232-237.
15. Greene HL. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Am J Cardiol. 1996;78:61-66.
16. Movsowitz C, Marchlinski FE. Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol. 1998;82: 41I-48I.
17. Steinberg JS, Martins J, Sadanandan S, Goldner B, Menchavez E, Domanski M, Russo A, Tullo N, Hallstrom A. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J. 2001;142:520-529.
18. Mazur A, Anderson ME, Bonney S, Roden DM. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol. 2001;37:1100-1105.
19. Pacifico A, Johnson JW, Stanton MS, Steinhaus DM, Gabler R, Church T, Henry PD. Comparison of results in two implantable defibrillators: Jewel 7219D Investigators. Am J Cardiol. 1998;82:875-880.
20. Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der LM, Holroyde MJ, Singer I, Pratt CM. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation. 2004;110:3646-3654.
21. Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverterdefibrillator in a placebo-controlled clinical trial. J Am Coll Cardiol. 2008;52:1076-1083.
22. Dorian P. Combination ICD and drug treatments-best options. Resuscitation. 2000;45:S3-S6.
23. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverterdefibrillators: incidence, management and prognostic implications. J Am Coll Cardiol. 1998;32:1909-1915.
24. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, Beckman KJ, Coromilas J, Lancaster S, Hallstrom AP. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001;103:2066-2071.
25. Villacastin J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R, Bueno H, Merino JL, Pastor A, Medina O, Tercedor L, Jimenez F, Delcan JL. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverterdefibrillators. Circulation. 1996;93:753-762.
26. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. Europace. 2000;2: 263-269.
27. Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J. 2006;27:3027-3032.
28. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN. Prevention of implantable-defibrillator shocks by treatment with sotalol: d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855-1862.
29. Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33:46-52.
30. Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol. 1998;82: 744-748.
31. Kettering K, Mewis C, Dornberger V, Vonthein R, Bosch RF, Kuhlkamp V. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2002;25: 1571-1576.
32. Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol. 2004;43:39-43.
33. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-171.
34. Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, Hall WJ, Andrews M, McNitt S, Daubert JP. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96:691-695.
35. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol. 2001;88:974-979.
36. Kowey PR, Singh BN. Dronedarone in patients with implantable defibrillators. Heart Rhythm Society 2004 Scientific Session, Late breaking Clinical Trials Oral Presentation. 2004.
37. O'Toole M, O'Neill G, Kluger J, Bonney S, Billing C. Efficacy and safety of oral dofetilide in patients with an implantable defibrillator: a multicenter study. Circulation. 1999;100:I-794.
38. Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006;114: 104-109.
39. Kuhlkamp V, Mewis C, Suchalla R, Mermi J, Dornberger V, Seipel L. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Int J Cardiol. 1999;69:271-279.
40. Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998;31:1672-1678.
41. Wood MA, Ellenbogen KA. Follow-up defibrillator testing for antiarrhythmic drugs: probability and uncertainty. Circulation. 2006;114: 98-100.
42. Epstein AE, Ellenbogen KA, Kirk KA, Kay GN, Dailey SM, Plumb VJ. Clinical characteristics and outcome of patients with high defibrillation thresholds: a multicenter study Circulation. 1992;86:1206-1216.
43. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987;114:8-17.
44. Pelosi F Jr, Oral H, Kim MH, Sticherling C, Horwood L, Knight BP, Michaud GF, Morady F, Strickberger SA. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol. 2000;11:736-740. (Pubitemid 30457480)
45. Qi XQ, Newman D, Dorian P. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. J Interv Card Electrophysiol. 1999;3:61-67.
46. Patel C, Yan GX, Kowey PR. Droendarone. Circulation. 2009;120: 636-644.
47. Bansch D, Castrucci M, Bocker D, Breithardt G, Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol. 2000;36: 557-565.
48. Rajawat YS, Patel VV, Gerstenfeld EP, Nayak H, Marchlinski FE. Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center. Pacing Clin Electrophysiol. 2004;27: 1670-1681.
49. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.
50. Morady F. Radio-frequency ablation as treatment for cardiac arrhythmias. N Engl J Med. 1999;340:534-544.
51. Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, Riva S, Moltrasio M, Cireddu M, Veglia F, Della BP. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation. 2008;117:462-469.
52. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657-2665.
53. Weinstock J, Wang PJ, Homoud MK, Link MS, Estes NA III. Clinical results with catheter ablation: AV junction, atrial fibrillation and ventricular tachycardia. J Interv Card Electrophysiol. 2003;9:275-288.
54. Estes NA III. Ablation after ICD implantation: bridging the gap between promise and practice. N Engl J Med. 2007;357:2717-2719.
55. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, ClappChanning N, Vidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
56. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.